Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study

Guardado en:

Detalles Bibliográficos
Publicado en:	Lancet Oncology vol. 26, no. 7 (Jul 2025), p. 847
Autor principal:	Elimova, Elena
Otros Autores:	Ajani, Jaffer, Burris, Howard, Denlinger, Crystal S, Iqbal, Syma, Yoon-Koo, Kang, Kim, Jwa Hoon, Lee, Keun-Wook, Lin, Bruce, Mehta, Rutika, Do-Youn, Oh, Sun Young Rha, Young Mi Seol, Yang, Lin, Ozog, Mark A, Garfin, Phillip M, Ku, Geoffrey
Publicado:	Elsevier Limited
Materias:	United States > US Monoclonal antibodies Prophylaxis Standard of care Cisplatin Metastasis Cytotoxicity Cancer therapies Bispecific antibodies Esophageal cancer Intravenous administration Adenocarcinoma Oxaliplatin Disease prevention Survival Metastases Kinases ErbB-2 protein Epidermal growth factor Medical prognosis Esophagus Disease control Diarrhea Response rates Biopsy Dosage Adverse events Safety Chemotherapy Tumors Patients 5-Fluorouracil Hepatitis
Acceso en línea:	Citation/Abstract Full Text Full Text - PDF
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!